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Interstitial keratitisAbstract We reported a Jordanian case of Cogan’s Syndrome (CS). A 22-year old male patient
presented with interstitial keratitis. The patient was treated successfully with topical steroids but
over the following months, he developed vertigo, sensorineural hearing loss (SNHL) and general-
ized vasculitis. This is the ﬁrst reported case of CS in Jordanian population.
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reserved.1. Introduction
Cogan’s Syndrome (CS) is a rare immune-mediated disease
characterized by ocular inﬂammation and audiovestibular dys-
function with or without vasculitis or other systemic manifes-
tations.3,4 The syndrome affects primarily young adults and
gives a clinical picture of systemic disease or vasculitis in 1/3
of patients. The prognosis is dominated by the risk of deﬁnitive
deafness and cardiovascular complications. We reported the
clinical and audiological ﬁndings for a Jordanian patient with
interstitial keratitis, vertigo and sensorineural hearing loss and
vasculitis. The clinical picture suggests the diagnosis of
Cogan’s Syndrome.2. Case report
A 22-year-old Jordanian male university student was admitted
to hospital in November 2010 complaining of burning sensa-
tion in his eyes and severe light sensitivity. Otherwise, the
patient was not known to have any other illness. His medical
and surgical history was positive for a previous history of
uneventful keratoplasty seven years ago. The initial diagnosis
was stromal keratitis. Therefore, topical steroids were used
for the treatment. The patient improved but three months
later, he had an attack of vertigo, vomiting, and he gradually
developed hearing loss and tinnitus. Pure tone audiogram
showed right moderate SNHL and left mild SNHL (Fig. 1).
The attack lasted for two weeks.
Three weeks later, a pure tone audiogram (Fig. 2) revealed
right moderate to severe SNHL mainly at low frequencies and
left mild to moderate SNHL mainly at low frequencies (Fig. 2).
Electrocochleography was conducted using click stimuli at
95 dB Normal Hearing Level (NHL). The results showed a
high summating potential/action potential (SP/AP) ratio in
the right ear of more than 60% and a mild elevation in the
SP/AP ratio in the left ear of about 40%. The obtained results
Figure 1 Pure tone audiogram: right moderate SNHL and left mild SNHL (high frequency 8 kHz).
Figure 2 Pure tone audiogram: right moderate to severe SNHL mainly at low frequencies and left mild to moderate SNHL mainly at
low frequencies.
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cochlear Meniere’s disease. CT and MRI of the brain and
the internal auditory meatus showed no structural lesions.
The patient was treated with betahistine dihydrochloride
16 mg three times daily. Although vertigo subsided after two
weeks, the hearing loss continued (Fig. 3). Six months after
the ﬁrst presentation, the patient presented to hospital with
fever, polyarthralgia, and recent weight loss. His echocardiog-
raphy showed trace mitral and tricuspid regurgitations, normal
pulmonary artery pressure, and mild to moderate left ventric-ular impairment (EF 40–45%). The laboratory investigations
of the patient are shown in Table 1. Serological tests for syph-
ilis and TB were negative (Table 2). Finally, the case was diag-
nosed as Cogan’s Syndrome. Therefore, the treatment
consisted of methotrexate (six 2.5 mg tabs, one day a week)
and folic acid for two months, and prednisolone 50 mg daily.
Due to hematuria and renal impairment, methotrexate was
replaced by azathioprine tablets 50 mg, three times daily.
There was an improvement in the patient vision and the gen-
eral symptoms of vasculitis but the hearing worsened.
Figure 3 Pure tone audiogram: bilateral severe to profound SNHL.
Table 1 Laboratory and radiological ﬁndings of the patient at the time of the initial presentation with vasculitis.
The parameter The result
WBC count 15.5 · 103 ml1 [leukocytosis (neutrophils 77%), shift to lift]
HTC 42%
PLT 538 · 103 ml1
ESR 152 mm/h
P-ANCA Negative
C-ANCA Negative
Anti-mitochondrial antibodies, serum <1/20, negative
Anti-acetylcholine receptor Abs, screening <1/20, negative
Blood ﬁlm Normal morphology
Bone marrow biopsy Normal bone marrow, no evidence of malignancy
CT scan of the neck and the abdomen Generalized lymphadenopathy
Table 2 Serological tests for syphilis and TB.
Laboratory results SI unit
Treponema pallidum hemagglutination, serum <1/80, negative
Rapid plasma regain (RPR) test, serum Negative
Mycobacterium tuberculosis DNA, PCR Negative
QuantiFERON-TB Gold Negative
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Cogan’s Syndrome was ﬁrst described by Dr. David G. Cogan
(1908–1993) in 1945 as a non-syphilitic interstitial keratitis
with vestibuloauditory symptoms.9 CS is rare, with fewer than
250 reported cases in the literature, and is mostly described in
young adult Caucasian patients of both sexes.4 CS is an extre-
mely rare disorder in Arabic and Middle Eastern countries.1
The novelty of our case report is that it is the ﬁrst reported
in Jordan (estimated population in 2012 was 6,388,000).The classical form of ocular involvement in CS is character-
ized by the interstitial keratitis. However, iritis or uveitis, scle-
ritis or episcleritis, and conjunctivitis have been also described,
and the atypical CS exists in the absence of interstitial kerati-
tis.4 Some systemic manifestations have been reported in asso-
ciation with CS, including vasculitis of the aorta leading to
aortic aneurysm and/or aortic valve regurgitation, fever,
arthralgia (or arthritis), lymphadenopathy, splenomegaly, skin
rash, and peripheral or central nervous system involvement.3,4
The ocular involvement in CS usually gives a good response
to topical corticosteroid therapy, while, systemic corticoste-
roids are reserved for unresponsive cases or those with poster-
ior uveitis, it was reported that poor long term ophthalmologic
outcomes due to CS are unusual in contrast to vestibuloaudi-
tory affection.3,7
Deafness is the most common serious outcome of CS and
systemic corticosteroid therapy is warranted as soon as possi-
ble after the onset of hearing loss,5,6,12,14 with the recommen-
dation of an initial dose therapy of 1 mg/kg (0.5–2) per day
of prednisone.4 If an improvement in hearing is observed
(objectively and subjectively), corticosteroids are gradually
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costeroid dose are contingent upon stable auditory acuity
and vestibular function.11 Certain patients may require long-
term corticosteroid therapy because of the recurrent hearing
loss during attempts to taper the prednisone dose,1 so, azathi-
oprine, cyclophosphamide, cyclosporine, methotrexate, and
tumor necrosis factor (TNF)-alpha blockers have been recom-
mended.4,12,13 Some patients may show unresponsiveness to
such a therapy, thereby resulting in severe hearing loss as in
our case.
In the presented case, as the others reported in the litera-
ture, the patient showed only leukocytosis and elevated eryth-
rocyte sedimentation rate (ESR). Sometimes, there is an
elevation in the level of C-reactive protein (CRP), but often
no alteration in inﬂammation parameters is observed, there-
fore, no speciﬁc diagnostic test is performed.2
The results of radiographic studies of CS cases, such as cra-
nial CT and MRI, are often normal; which could be useful in
the exclusion of other causes of vestibuloauditory symptoms
such as stroke or neoplasm.5
CS is a cause of progressive deafness; it is assumed to be an
‘‘autoimmune disease’’.8,10 However, this disease needs to be
accurately documented and described in order to offer a better
understanding of the pathogenesis and to contribute toward
developing efﬁcacious early treatment. Follow-up of patients
presenting sudden or rapidly progressive hearing loss, with
or without vestibular symptoms, is also crucial, because these
symptoms could represent the initial manifestation of CS.
Since about two thirds of patients meet the classic diagnostic
criteria for CS,5 the follow-up of patients who present only
vestibuloauditory symptoms should be guaranteed for at least
two years.
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